drugset / Trial / NCT02493855
Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the effect of ribavirin on second phase plasma hepatitis C virus (HCV) ribonucleic acid (RNA) decline in participants who receive ombitasvir/ABT-450/ritonavir and dasabuvir with full dose ribavirin, low dose ribavirin or without ribavirin for 2 weeks in treatment-naive HCV genotype (GT) 1a-infected adults.
Timeline
- Start
- 2015-06
- Primary completion
- 2016-04
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ribavirin | Small molecule | 600 mg | — |
| Subject | Ribavirin | Small molecule | 1000 mg | — |
| Subject | Ribavirin | Small molecule | 1200 mg | — |
| Background | Ritonavir | Other / unclassified | 100 mg | — |
| Background | dasabuvir | Small molecule | 250 mg | — |
| Background | ombitasvir | Small molecule | 25 mg | — |
| Background | paritaprevir | Small molecule | 150 mg | — |